. 2024 Jan 1;16(1):209.

doi: 10.3390/cancers16010209.

Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer

Christos Damaskos^{1

2}, Iason Psilopatis³, Anna Garmpi⁴, Dimitrios Dimitroulis⁵, Konstantinos Nikolettos⁶, Kleio Vrettou⁷, Panagiotis Sarantis⁸, Evangelos Koustas⁸, Gregory Kouraklis⁹, Efstathios A Antoniou^{2

10}, Michail V Karamouzis⁸, Nikolaos Nikolettos⁶, Panagiotis Tsikouras⁶, Georgios Marinos¹¹, Emmanouil Kontomanolis⁶, Konstantinos Kontzoglou^{2

5}, Nikolaos Garmpis^{2

10}

Affiliations

¹ Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece.
² N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
³ Department of Obstetrics and Gynecology, University Erlangen, Universitaetsstrasse 21-23, 91054 Erlangen, Germany.
⁴ First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
⁵ Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
⁶ Department of of Obstetrics and Gynecology, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
⁷ Department of Cytopathology, Sismanogleio General Hospital, 15126 Athens, Greece.
⁸ Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
⁹ Department of Surgery, Evgenideio Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
¹⁰ Department of General Surgery and HPB Surgery of Adults and Children, Hygeia Hospital, 15123 Athens, Greece.
¹¹ Department of Hygiene, Epidemiology and Medical Statistics, National and Kapodistrian University of Athens, 11527 Athens, Greece.

PMID: 38201636
PMCID: PMC10777907
DOI: 10.3390/cancers16010209

Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer

Christos Damaskos et al. Cancers (Basel). 2024.

. 2024 Jan 1;16(1):209.

doi: 10.3390/cancers16010209.

Authors

Affiliations

¹ Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece.
² N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
³ Department of Obstetrics and Gynecology, University Erlangen, Universitaetsstrasse 21-23, 91054 Erlangen, Germany.
⁴ First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
⁵ Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
⁶ Department of of Obstetrics and Gynecology, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
⁷ Department of Cytopathology, Sismanogleio General Hospital, 15126 Athens, Greece.
⁸ Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
⁹ Department of Surgery, Evgenideio Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
¹⁰ Department of General Surgery and HPB Surgery of Adults and Children, Hygeia Hospital, 15123 Athens, Greece.
¹¹ Department of Hygiene, Epidemiology and Medical Statistics, National and Kapodistrian University of Athens, 11527 Athens, Greece.

PMID: 38201636
PMCID: PMC10777907
DOI: 10.3390/cancers16010209

Abstract

Background/aim: Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis and progression. In this study, we aimed at assessing the clinical importance of HDAC-2 in triple negative breast cancer.

Materials and methods: A total of 138 breast cancer specimens were examined on an immunohistochemical basis. A statistical analysis was performed in order to examine the association between HDAC-2 and the survival and clinicopathological features of the patients.

Results: Increased HDAC-2 expression was observed in every fourth case of triple negative breast cancer with positive HDAC-2 staining, whereas only 12 out of 98 non-triple negative breast cancer samples showed high HDAC-2 expression. HDAC-2 overexpression correlated with prolonged overall survival (OS) and disease-free survival (DFS) in triple negative breast cancer.

Conclusions: High HDAC-2 levels in triple negative breast cancer seem to positively influence patient survival, disease stage and recurrence.

Keywords: HDAC; breast; cancer; clinicopathological; deacetylase; histone; negative; triple.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

**Figure 1**
Histone deacetylases function.

**Scheme 1**
Patient selection criteria, alongside a flow chart of the current study.

**Figure 2**
HDAC-2 immunohistochemical expression in triple negative breast cancer tissue (×200).

**Figure 3**
Immunohistochemical HDAC-2 expression level in triple negative breast cancer.

**Figure 4**
Kaplan–Meier estimates for DFS and OS according to HDAC-2 expression level.

See this image and copyright information in PMC

Cited by

Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing.
Larose ÉA, Hua X, Yu S, Pillai AT, Yi Z, Yu H. Larose ÉA, et al. Cancer Drug Resist. 2025 Mar 6;8:11. doi: 10.20517/cdr.2024.180. eCollection 2025. Cancer Drug Resist. 2025. PMID: 40201309 Free PMC article. Review.
Dissecting the epigenetic orchestra of HDAC isoforms in breast cancer development: a review.
Debbarma M, Sarkar K, Sil SK. Debbarma M, et al. Med Oncol. 2024 Nov 12;42(1):1. doi: 10.1007/s12032-024-02553-9. Med Oncol. 2024. PMID: 39532757 Review.
Investigating Potential Cancer Therapeutics: Insight into Histone Deacetylases (HDACs) Inhibitions.
Ahmad B, Saeed A, Al-Amery A, Celik I, Ahmed I, Yaseen M, Khan IA, Al-Fahad D, Bhat MA. Ahmad B, et al. Pharmaceuticals (Basel). 2024 Mar 29;17(4):444. doi: 10.3390/ph17040444. Pharmaceuticals (Basel). 2024. PMID: 38675404 Free PMC article.

References

1. American Cancer Society . Key Statistics for Breast Cancer: American Cancer Society. American Cancer Society; Atlanta, GA, USA: 2022.
1. Elias A.D. Triple-negative breast cancer: A short review. Am. J. Clin. Oncol. 2010;33:637–645. doi: 10.1097/COC.0b013e3181b8afcf. - DOI - PubMed
1. Dass S.A., Tan K.L., Selva Rajan R., Mokhtar N.F., Mohd Adzmi E.R., Wan Abdul Rahman W.F., Tengku Din T.A.D.A., Balakrishnan V. Triple negative breast cancer: A review of present and future diagnostic modalities. Medicina. 2021;57:62. doi: 10.3390/medicina57010062. - DOI - PMC - PubMed
1. American Cancer Society . Triple Negative Breast Cancer: American Cancer Society. American Cancer Society; Atlanta, GA, USA: 2022.
1. Yang R., Li Y., Wang H., Qin T., Yin X., Ma X. Therapeutic progress and challenges for triple negative breast cancer: Targeted therapy and immunotherapy. Mol. Biomed. 2022;3:8. doi: 10.1186/s43556-022-00071-6. - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer

Affiliations

Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources